ARTICLES BY PERRY YIN
-
![road-closed-barrier]( "4 Barriers To Cell And Gene Therapy Development For Rare Diseases — And How To Overcome Them")
4 Barriers To Cell And Gene Therapy Development For Rare Diseases — And How To Overcome Them9/27/2018A number of challenges are hindering efforts to develop cell and gene therapies to treat rare diseases. While these challenges may seem common across other drug markets, in the case of rare diseases, they are exacerbated by limited patient populations
-
![Cell]( "4 Future Scenarios For Cell And Gene Therapy Adoption")
4 Future Scenarios For Cell And Gene Therapy Adoption8/8/2018Cell and gene therapies: Will their use become ubiquitous, changing the landscape forever as many have promised? Or will applications be confined to rare diseases as they have been thus far?
-
![filling_test_tubes_450x300]( "3 Keys To Scale-Up CAR T-Cell Therapy Manufacturing")
3 Keys To Scale-Up CAR T-Cell Therapy Manufacturing11/27/2017Kymriah and Yescarta have overcome the first hurdle to commercialization by receiving the FDA’s stamp of approval. Now, Gilead and Novartis must prove they can handle the supply chain complexities involved with manufacturing and distributing these personalized, time-sensitive therapies to wider patient populations.
Perry Yin
Perry Yin, Ph.D., is a life sciences expert at PA Consulting Group, where he leads the Cell and Gene Therapy group. Yin has extensive experience developing cell and gene therapies, leading interdisciplinary teams to develop technologies like CRISPR and stem cell-based therapies from concept to animal testing for both cancer and regenerative medicine applications. He has also been involved in product commercialization, where he helped to raise capital and supported licensing and M&A deals for three development- and clinical-stage companies. Contact him on LinkedIn at https://www.linkedin.com/in/yinperry/.